The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Otsuka Files IgA Nephropathy Drug Sibeprenlimab in US
Otsuka Pharmaceutical said on March 31 that it has filed its monoclonal antibody sibeprenlimab for the treatment of adults with immunoglobulin A (IgA) nephropathy in the US. The submission, made on March 28, rides on the back of the results…
To read the full story
Related Article
- Otsuka’s Sibeprenlimab Earns FDA’s Accelerated Nod for IgAN
November 27, 2025
- Otsuka’s Sibeprenlimab Scores Positive Results in PIII: Interim Analysis
June 9, 2025
- Otsuka Plans US Filing of IgA Nephropathy Drug in H1 2025
November 20, 2024
- Otsuka’s IgA Nephropathy Drug Makes Mark in PIII, Eyes Accelerated Path
October 23, 2024
- Otsuka’s IgA Nephropathy Drug Gets FDA Breakthrough Tag
February 19, 2024
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…